IKT vs RL · $215.2M cap vs P/E 24, rev $8.11B
Inhibikase Therapeutics Inc (IKT) versus Ralph Lauren Corp Class A (RL) — a side-by-side from cached financials, not a winner call.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Ralph Lauren Corp Class A (RL) is a apparel manufacturing company listed on US.
Latest reported IKT revenue for 2024-12-31 was $0. Net income was -$27.5M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. IKT currently screens at market cap $215.2M.
Latest reported RL revenue for 2026-03-28 was $8.11B. Net income was $941.1M. Revenue was up 14.6% from 2025-03-29 to 2026-03-28. RL currently screens at market cap $16.95B and trailing P/E 24.1.
IKT currently screens at market cap $215.2M. RL currently screens at market cap $16.95B and trailing P/E 24.1.
Not investment advice. Open the IKT and RL stock pages for the full models.
Not investment advice.